Registered number
10715672
CHINA UK MEDICAL INNOVATION TECHNOLOGY LTD
Filleted Accounts
30 April 2024
CHINA UK MEDICAL INNOVATION TECHNOLOGY LTD
Registered number: 10715672
Balance Sheet
as at 30 April 2024
Notes 2024 2023
£ £
Fixed assets
Tangible assets 3 615,938 629,359
615,938 629,359
Current assets
Debtors 4 20,000 -
Cash at bank and in hand 5,441 42,673
25,441 42,673
Creditors: amounts falling due within one year 5 (720) (600)
Net current assets 24,721 42,073
Total assets less current liabilities 640,659 671,432
Creditors: amounts falling due after more than one year 6 (723,318) (719,498)
Provisions for liabilities - -
Net liabilities (82,659) (48,066)
Capital and reserves
Called up share capital 100 100
Profit and loss account (82,759) (48,166)
Shareholders' funds (82,659) (48,066)
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
BO LIU
Director
Approved by the board on 28 January 2025
CHINA UK MEDICAL INNOVATION TECHNOLOGY LTD
Notes to the Accounts
for the year ended 30 April 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Leasehold land and buildings over 50 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company - -
3 Tangible fixed assets
Land and buildings Plant and machinery etc Motor vehicles Total
£ £ £ £
Cost
At 1 May 2023 671,043 - - 671,043
Additions - - - -
Surplus on revaluation - - - -
Disposals - - - -
At 30 April 2024 671,043 - - 671,043
Depreciation
At 1 May 2023 41,684 - - 41,684
Charge for the year 13,421 - - 13,421
Surplus on revaluation - - - -
On disposals - - - -
At 30 April 2024 55,105 - - 55,105
Net book value
At 30 April 2024 615,938 - - 615,938
At 30 April 2023 629,359 - - 629,359
4 Debtors 2024 2023
£ £
Other debtors 20,000 -
20,000 -
5 Creditors: amounts falling due within one year 2024 2023
£ £
Other creditors 720 600
720 600
6 Creditors: amounts falling due after one year 2024 2023
£ £
Bank loans 300,000 300,000
Director's Loan Account 109,600 44,600
Other creditors 313,718 374,898
723,318 719,498
7 Controlling party
The company is controlled by KAIXIANG LIU (100%)
CHINA UK MEDICAL INNOVATION TECHNOLOGY LTD 10715672 false 2023-05-01 2024-04-30 2024-04-30 VT Final Accounts April 2024 BO LIU No description of principal activity 10715672 2022-05-01 2023-04-30 10715672 core:WithinOneYear 2023-04-30 10715672 core:AfterOneYear 2023-04-30 10715672 core:ShareCapital 2023-04-30 10715672 core:RetainedEarningsAccumulatedLosses 2023-04-30 10715672 2023-05-01 2024-04-30 10715672 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 10715672 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 10715672 bus:Director40 2023-05-01 2024-04-30 10715672 1 2023-05-01 2024-04-30 10715672 2 2023-05-01 2024-04-30 10715672 core:LandBuildings 2023-05-01 2024-04-30 10715672 core:PlantMachinery 2023-05-01 2024-04-30 10715672 core:Vehicles 2023-05-01 2024-04-30 10715672 bus:FRS102 2023-05-01 2024-04-30 10715672 bus:FilletedAccounts 2023-05-01 2024-04-30 10715672 2024-04-30 10715672 core:WithinOneYear 2024-04-30 10715672 core:AfterOneYear 2024-04-30 10715672 core:ShareCapital 2024-04-30 10715672 core:RetainedEarningsAccumulatedLosses 2024-04-30 10715672 core:LandBuildings 2024-04-30 10715672 core:PlantMachinery 2024-04-30 10715672 core:Vehicles 2024-04-30 10715672 2023-04-30 10715672 core:LandBuildings 2023-04-30 10715672 core:PlantMachinery 2023-04-30 10715672 core:Vehicles 2023-04-30 iso4217:GBP xbrli:pure